|
| 36100310 | Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. | J Immunother Cancer | 2022 |
| 32395117 | Preclinical Studies of the Off-Target Reactivity of AFP<sub>158</sub>-Specific TCR Engineered T Cells. | Front Immunol | 2020 |
| 32425926 | Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit. | Front Immunol | 2020 |
| 29799009 | Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironments in Chinese NSCLC patients. | Nat Commun | 2018 |
| 27399333 | Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies. | Oncogene | 2017 |
| 28460468 | PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC). | Oncotarget | 2017 |
| 29242501 | High-throughput RNA sequencing reveals distinct gene signatures in active IgG4-related disease. | Sci Rep | 2017 |
| 29293853 | Three-Dimensional Simulation of Land Drains as a Preferential Pathway for Vapor Intrusion into Buildings. | J Environ Qual | 2017 |
| 29187883 | Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer. | J Cancer | 2017 |
| 26744529 | A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors. | Cancer Res | 2016 |
| 26556607 | In Vivo Therapeutic Success of MicroRNA-155 Antagomir in a Mouse Model of Lupus Alveolar Hemorrhage. | Arthritis Rheumatol | 2016 |
| 26578606 | BubbleTree: an intuitive visualization to elucidate tumoral aneuploidy and clonality using next generation sequencing data. | Nucleic Acids Res | 2016 |
| 26663909 | Identification of Cyclin-Dependent Kinase 1 as a Novel Regulator of Type I Interferon Signaling in Systemic Lupus Erythematosus. | Arthritis Rheumatol | 2016 |
| 27481557 | Identification of the long noncoding RNA NEAT1 as a novel inflammatory regulator acting through MAPK pathway in human lupus. | J Autoimmun | 2016 |
| 27226090 | Type I IFNs Regulate Inflammation, Vasculopathy, and Fibrosis in Chronic Cutaneous Graft-versus-Host Disease. | J Immunol | 2016 |
| 27093186 | Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer. | PLoS Genet | 2016 |
| 25937444 | Low-frequency coding variants at 6p21.33 and 20q11.21 are associated with lung cancer risk in Chinese populations. | Am J Hum Genet | 2015 |
| 26653219 | HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma. | J Transl Med | 2015 |
| 26587322 | A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4<sup>+</sup> T cell receptor repertoire clonality. | Oncoimmunology | 2015 |
| 26528288 | Predominant Role of Plasmacytoid Dendritic Cells in Stimulating Systemic Autoimmunity. | Front Immunol | 2015 |
| 26315540 | Type I Interferon Inhibition of MicroRNA-146a Maturation Through Up-Regulation of Monocyte Chemotactic Protein-Induced Protein 1 in Systemic Lupus Erythematosus. | Arthritis Rheumatol | 2015 |
| 26257170 | Neutrophils Regulate Humoral Autoimmunity by Restricting Interferon-γ Production via the Generation of Reactive Oxygen Species. | Cell Rep | 2015 |
| 25993119 | Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis. | J Invest Dermatol | 2015 |
| 25963922 | MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis. | Nat Commun | 2015 |
| 23434567 | A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. | Ann Rheum Dis | 2014 |
| 25193511 | MEDI-573, alone or in combination with mammalian target of rapamycin inhibitors, targets the insulin-like growth factor pathway in sarcomas. | Mol Cancer Ther | 2014 |
| 24757153 | Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathies. | Arthritis Rheumatol | 2014 |
| 24559157 | Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. | Arthritis Res Ther | 2014 |
| 24571613 | Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma. | BMC Cancer | 2014 |
| 24289491 | MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D. | Pigment Cell Melanoma Res | 2014 |
| 24357810 | Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis. | Rheumatology (Oxford) | 2014 |
| 24431284 | The plasma cell signature in autoimmune disease. | Arthritis Rheumatol | 2014 |
| 24076269 | Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. | Pharmacol Ther | 2014 |
| 24118906 | The evaluation of efficacy and safety of sunitinib on EGFR-TKI pretreated advanced non-small cell lung cancer patients in China. | Clin Respir J | 2014 |
| 23283488 | EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter. | Stem Cells Transl Med | 2013 |
| 24200637 | Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients. | Cancer Genet | 2013 |
| 23990866 | Circulating tumor cells: application as a biomarker for molecular characterization and predictor of survival in an all-comer solid tumor phase I clinical study. | PLoS One | 2013 |
| 23732751 | Molecular profiling to diagnose a case of atypical dermatomyositis. | J Invest Dermatol | 2013 |
| 23400715 | Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. | Arthritis Rheum | 2013 |
| 23511714 | Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-α receptor antibody. | Clin Pharmacol Ther | 2013 |
| 23582400 | microRNA-mediated regulation of innate immune response in rheumatic diseases. | Arthritis Res Ther | 2013 |
| 23201923 | Type I interferons in Sjögren's syndrome. | Autoimmun Rev | 2013 |
| 21881594 | Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. | Genes Immun | 2012 |
| 23171592 | Genomic signatures characterize leukocyte infiltration in myositis muscles. | BMC Med Genomics | 2012 |
| 23083033 | Biomarkers for systemic lupus erythematosus. | Int J Rheum Dis | 2012 |
| 23110058 | Angiogenic factor AGGF1 promotes therapeutic angiogenesis in a mouse limb ischemia model. | PLoS One | 2012 |
| 22736314 | Identification of microRNA-31 as a novel regulator contributing to impaired interleukin-2 production in T cells from patients with systemic lupus erythematosus. | Arthritis Rheum | 2012 |
| 22851696 | TRAF6-dependent Act1 phosphorylation by the IκB kinase-related kinases suppresses interleukin-17-induced NF-κB activation. | Mol Cell Biol | 2012 |
| 22574157 | The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA. | PLoS One | 2012 |
| 22235269 | Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. | PLoS One | 2012 |